Specification

Introduction In countries such as Australia, the UK, and Canada, public funding decisions for health technologies (e.g., pharmaceuticals) are based predominantly on cost-effectiveness data. National reimbursement bodies in these countries, such as the Pharmaceutical Benefits Advisory Committee in Australia and National Institute for Health and Clinical Excellence in the UK, provide guidance to the government